Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease

Experimental Neurology

Volumn 255, Issue , 2014, Pages 154-160

  Feng, Ze Jun ^a   Zhang, Xiaoqun ^a   Chergui, Karima ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acetylcholine; Allosteric modulation; GABA; Glutamate; NMDA receptors; Parkinson's disease; Striatum

Indexed keywords

DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; PROTEIN GLUN2D; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; GABAERGIC TRANSMISSION; INTERNEURON; MALE; MOUSE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; WHOLE CELL;

ACETYLCHOLINE; ALLOSTERIC MODULATION; GABA; GLUTAMATE; NMDA RECEPTORS; PARKINSON'S DISEASE; STRIATUM;

ANIMALS; CORPUS STRIATUM; MICE; NEURONS; PARKINSONIAN DISORDERS; PATCH-CLAMP TECHNIQUES; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84896956298     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.03.001     Document Type: Article

References (28)

1. Addy C., Assaid C., Hreniuk D., Stroh M., Xu Y., Herring W.J., Ellenbogen A., Jinnah H.A., Kirby L., Leibowitz M.T., Stewart R.M., Tarsy D., Tetrud J., Stoch S.A., Gottesdiener K., Wagner J. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J. Clin. Pharmacol. 2009, 49:856-864.
2. Bagetta V., Ghiglieri V., Sgobio C., Calabresi P., Picconi B. Synaptic dysfunction in Parkinson's disease. Biochem. Soc. Trans. 2010, 38:493-497.
3. Bloomfield C., O'Donnell P., French S.J., Totterdell S. Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-d-aspartate 2D but not N-methyl-d-aspartate 2C receptor subunits. Neuroscience 2007, 150:639-646.
4. Calabresi P., Di Filippo M., Gallina A., Wang Y., Stankowski J.N., Picconi B., Dawson V.L., Dawson T.M. New synaptic and molecular targets for neuroprotection in Parkinson's disease. Mov. Disord. 2013, 28:51-60.
5. Chergui K. Dopamine induces a GluN2A-dependent form of long-term depression of NMDA synaptic responses in the nucleus accumbens. Neuropharmacology 2011, 60:975-981.
6. Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 2001, 11:327-335.
7. Dehorter N., Guigoni C., Lopez C., Hirsch J., Eusebio A., Ben-Ari Y., Hammond C. Dopamine-deprived striatal GABAergic interneurons burst and generate repetitive gigantic IPSCs in medium spiny neurons. J. Neurosci. 2009, 29:7776-7787.
8. English D.F., Ibanez-Sandoval O., Stark E., Tecuapetla F., Buzsaki G., Deisseroth K., Tepper J.M., Koos T. GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons. Nat. Neurosci. 2012, 15:123-130.
9. Gardoni F., Ghiglieri V., Luca M.d., Calabresi P., Anders B., Cenci M.A. Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Progress in Brain Research 2010, 169-182. Elsevier.
10. Gogas K.R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. 2006, 6:68.
11. Hallett P.J., Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2004, 102:155-174.
12. Kawaguchi Y. Physiological, morphological, and histochemical characterization of 3 classes of interneurons in rat neostriatum. J. Neurosci. 1993, 13:4908-4923.
13. Kohr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res. 2006, 326:439-446.
14. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penney J.B., Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 1995, 15:5297-5307.
15. Loftis J.M., Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003, 97:55-85.
16. Luo R., Janssen M.J., Partridge J.G., Vicini S. Direct and GABA-mediated indirect effects of nicotinic ACh receptor agonists on striatal neurones. J. Physiol. 2013, 591:203-217.
17. Misra C., Brickley S.G., Farrant M., Cull-Candy S.G. Identification of subunits contributing to synaptic and extrasynaptic NMDA receptors in Golgi cells of the rat cerebellum. J. Physiol. 2000, 524:147-162.
18. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12:529-540.
19. Mullasseril P., Hansen K.B., Vance K.M., Ogden K.K., Yuan H., Kurtkaya N.L., Santangelo R., Orr A.G., Le P., Vellano K.M., Liotta D.C., Traynelis S.F. A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat. Commun. 2010, 1:90.
20. Paille V., Picconi B., Bagetta V., Ghiglieri V., Sgobio C., Di Filippo M., Viscomi M.T., Giampa C., Fusco F.R., Gardoni F., Bernardi G., Greengard P., Di Luca M., Calabresi P. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J. Neurosci. 2010, 30:14182-14193.
21. Paoletti P. Molecular basis of NMDA receptor functional diversity. Eur. J. Neurosci. 2011, 33:1351-1365.
22. Paoletti P., Neyton J. NMDA receptor subunits: function and pharmacology. Curr. Opin. Pharmacol. 2007, 7:39-47.
23. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic, San Diego.
24. Pisani A., Bernardi G., Ding J., Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007, 30:545-553.
25. Standaert D.G., Landwehrmeyer G.B., Kerner J.A., Penney J.B., Young A.B. Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res. Mol. Brain Res. 1996, 42:89-102.
26. Taverna S., Ilijic E., Surmeier D.J. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J. Neurosci. 2008, 28:5504-5512.
27. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. 2008, 105:2163-2168.
28. Zhang X., Feng Z.-J., Chergui K. GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease. J. Neurochem. 2014, (n/a-n/a).